{{distinguish|calretinin}}
{{PBB|geneid=811}}

'''Calreticulin''' also known as  '''calregulin''', '''CRP55''', '''CaBP3''', '''calsequestrin-like protein''', and '''endoplasmic reticulum resident protein 60''' (ERp60) is a [[protein]] that in humans is encoded by the ''CALR'' [[gene]].<ref name="pmid2365822">{{cite journal | author = McCauliffe DP, Zappi E, Lieu TS, Michalak M, Sontheimer RD, Capra JD | title = A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal RAL-1 antigen and an aplysia "memory molecule" | journal = J. Clin. Invest. | volume = 86 | issue = 1 | pages = 332–5 | year = 1990 | month = July | pmid = 2365822 | pmc = 296725 | doi = 10.1172/JCI114704 | url =  }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: calreticulin| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=811| accessdate = }}</ref>

Calreticulin is a multifunctional [[protein]] that binds [[calcium|Ca<sup>2+</sup>]] [[ion]]s (a [[second messenger]] in [[signal transduction]]), rendering it inactive. The Ca<sup>2+</sup> is bound with low [[Chemical affinity|affinity]], but high [[Valence (chemistry)|capacity]], and can be released on a signal (see [[inositol triphosphate]]). Calreticulin is located in storage compartments associated with the [[endoplasmic reticulum]].<ref name="entrez"/>

The term "Mobilferrin"<ref>{{MeshName|Mobilferrin}}</ref> is considered to be the same as calreticulin by some sources.<ref>{{cite journal |author=Beutler E, West C, Gelbart T |title=HLA-H and associated proteins in patients with hemochromatosis |journal=Mol. Med. |volume=3 |issue=6 |pages=397–402 |year=1997 |pmid=9234244 |doi= |pmc=2230203}}</ref>

== Function ==

Calreticulin binds to misfolded proteins and prevents them from being exported from the [[endoplasmic reticulum]] to the [[Golgi apparatus]].

A similar quality-control chaperone, [[calnexin]], performs the same service for soluble proteins as does calreticulin.  Both proteins, calnexin and calreticulin, have the function of binding to [[oligosaccharide]]s containing terminal glucose residues, thereby targeting them for degradation.  In normal cellular function, trimming of glucose residues off the core oligosaccharide added during N-linked [[glycosylation]] is a part of protein processing.  If "overseer" enzymes note that residues are misfolded, proteins within the [[Rough endoplasmic reticulum|RER]] will re-add glucose residues so that other calreticulin/calnexin can bind to these proteins and prevent them from proceeding to the Golgi.  This leads these aberrantly folded proteins down a path whereby they are targeted for degradation.

Studies on transgenic mice reveal that calreticulin is a cardiac embryonic gene that is essential during development.<ref name="pmid12445456">{{cite journal | author = Michalak M, Lynch J, Groenendyk J, Guo L, Robert Parker JM, Opas M | title = Calreticulin in cardiac development and pathology | journal = Biochim. Biophys. Acta | volume = 1600 | issue = 1–2 | pages = 32–7 | year = 2002 | month = November | pmid = 12445456 | doi = 10.1016/S1570-9639(02)00441-7| url =  }}</ref>

=== Transcription regulation ===

Calreticulin is also found in the nucleus, suggesting that it may have a role in transcription regulation. Calreticulin binds to the [[synthetic peptide]] KLGFFKR, which is almost identical to an amino acid sequence in the [[DNA-binding domain]] of the superfamily of [[nuclear receptor]]s. The [[N-terminus|amino terminus]] of calreticulin interacts with the DNA-binding domain of the [[glucocorticoid receptor]] and prevents the receptor from binding to its specific [[glucocorticoid response element]]. Calreticulin can inhibit the binding of [[androgen receptor]] to its hormone-responsive DNA element and can inhibit androgen receptor and [[retinoic acid receptor]] transcriptional activities in vivo, as well as retinoic acid-induced neuronal differentiation. Thus, calreticulin can act as an important modulator of the regulation of gene transcription by nuclear hormone receptors.

== Clinical significance ==

Calreticulin binds to [[antibody|antibodies]] in certain sera of [[Lupus erythematosus|systemic lupus]] and [[Sjögren's syndrome|Sjogren]] patients that contain [[Anti-SSA/Ro autoantibodies|anti-Ro/SSA antibodies]]. Systemic lupus erythematosus is associated with increased autoantibody titers against calreticulin, but calreticulin is not a Ro/SS-A antigen. Earlier papers referred to calreticulin as an Ro/SS-A antigen, but this was later disproven. Increased autoantibody titer against human calreticulin is found in infants with complete congenital heart block of both the [[IgG]] and [[IgM]] classes.<ref>{{cite web | title = Entrez Gene: CALR calreticulin| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=811| accessdate = }}</ref>

== Role in cancer ==

Calreticulin (CRT) is expressed in many cancer cells and plays a role to promote [[macrophage]]s to engulf hazardous cancerous cells. The reason why most of the cells are not destroyed is the presence of another molecule with signal [[CD47]], which blocks CRT.  Hence antibodies that block CD47 might be useful as a cancer treatment. In mice models of [[myeloid leukemia]] and [[non-Hodgkin’s lymphoma]], anti-CD47 were effective in clearing cancer cells while normal cells were unaffected.<ref name="pmid21178137">{{cite journal | author = Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL | title = Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47 | journal = Sci Transl Med | volume = 2 | issue = 63 | pages = 63ra94 | year = 2010 | month = December | pmid = 21178137 | doi = 10.1126/scitranslmed.3001375 | laysummary = http://med.stanford.edu/ism/2010/december/crt-signal.html | laysource = Stanford School of Medicine }}</ref>

== Interactions ==

Calreticulin has been shown to [[Protein-protein interaction|interact]] with [[Perforin]]<ref name=pmid9671507>{{cite journal |last=Andrin |first=C |authorlink= |coauthors=Pinkoski M J, Burns K, Atkinson E A, Krahenbuhl O, Hudig D, Fraser S A, Winkler U, Tschopp J, Opas M, Bleackley R C, Michalak M |year=1998|month=Jul. |title=Interaction between a Ca2+-binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules |journal=Biochemistry |volume=37 |issue=29 |pages=10386–94 |publisher= |location = UNITED STATES| issn = 0006-2960| pmid = 9671507 |doi = 10.1021/bi980595z | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> and [[NK2 homeobox 1]].<ref name=pmid9988700>{{cite journal |last=Perrone |first=L |authorlink= |coauthors=Tell G, Di Lauro R |year=1999|month=Feb. |title=Calreticulin enhances the transcriptional activity of thyroid transcription factor-1 by binding to its homeodomain |journal=J. Biol. Chem. |volume=274 |issue=8 |pages=4640–5 |publisher= |location = UNITED STATES| issn = 0021-9258| pmid = 9988700 | bibcode = | oclc =| id = | url = | language = | format = | accessdate = | laysummary = | laysource = | laydate = | quote = |doi=10.1074/jbc.274.8.4640 }}</ref>

{{-}}
==References==
{{Reflist|2}}

==Further reading==
{{refbegin|2}}
*{{cite journal  | author=Del Bem LEV|title=The evolutionary history of calreticulin and calnexin genes in green plants |journal=Genetica |volume=139 |issue= 2 |pages= 225–9 |year= 2011 |pmid= 21222018 |doi=10.1007/s10709-010-9544-y  }}
*{{cite journal  | author=Coppolino MG, Dedhar S |title=Calreticulin |journal=Int. J. Biochem. Cell Biol. |volume=30 |issue= 5 |pages= 553–8 |year= 1998 |pmid= 9693955 |doi=10.1016/S1357-2725(97)00153-2  }}
*{{cite journal  |author=Brucato A |title=Congenital Heart Block Not Associated with Anti-Ro/La Antibodies: Comparison with Anti-Ro/La-positive Cases |journal=J. Rheumatol. |volume=36 |issue= 8 |pages= 1744–8 |year= 2009 |pmid= 19567621 |doi= 10.3899/jrheum.080737  |author-separator=,  |author2=Grava C  |author3=Bortolati M  |display-authors=3  |last4=Ikeda  |first4=K.  |last5=Milanesi  |first5=O.  |last6=Cimaz  |first6=R.  |last7=Ramoni  |first7=V.  |last8=Vignati  |first8=G.  |last9=Martinelli  |first9=S.  |pmc=2798588 }}
*{{cite journal  |author=Peng RQ |title=Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer |journal=World J. Gastroenterol. |volume=16 |issue= 19 |pages= 2428–34 |year= 2010 |pmid= 20480531 |doi=10.3748/wjg.v16.i19.2428  |author-separator=,  |author2=Chen YB  |author3=Ding Y  |display-authors=3  |last4=Zhang  |first4=R  |last5=Zhang  |first5=X  |last6=Yu  |first6=XJ  |last7=Zhou  |first7=ZW  |last8=Zeng  |first8=YX  |last9=Zhang  |first9=XS  |pmc=2874150  }}
*{{cite journal  |author=Tarr JM |title=A mechanism of release of calreticulin from cells during apoptosis |journal=J. Mol. Biol. |volume=401 |issue= 5 |pages= 799–812 |year= 2010 |pmid= 20624402 |doi= 10.1016/j.jmb.2010.06.064  |author-separator=,  |author2=Young PJ  |author3=Morse R  |display-authors=3  |last4=Shaw  |first4=Debra J.  |last5=Haigh  |first5=Richard  |last6=Petrov  |first6=Peter G.  |last7=Johnson  |first7=Steven J.  |last8=Winyard  |first8=Paul G.  |last9=Eggleton  |first9=Paul }}
*{{cite journal  |author=Abd Alla J |title=Calreticulin enhances B2 bradykinin receptor maturation and heterodimerization |journal=Biochem. Biophys. Res. Commun. |volume=387 |issue= 1 |pages= 186–90 |year= 2009 |pmid= 19580784 |doi= 10.1016/j.bbrc.2009.07.011  |author-separator=,  |author2=Reeck K  |author3=Langer A  |display-authors=3  |last4=Streichert  |first4=Thomas  |last5=Quitterer  |first5=Ursula }}
*{{cite journal  |author=Caramelo JJ, Parodi AJ |title=Getting In and Out from Calnexin/Calreticulin Cycles |journal=J. Biol. Chem. |volume=283 |issue= 16 |pages= 10221–5 |year= 2008 |pmid= 18303019 |doi= 10.1074/jbc.R700048200  |pmc=2447651 }}
*{{cite journal  |author=Du XL |title=Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma |journal=Oncogene |volume=28 |issue= 42 |pages= 3714–22 |year= 2009 |pmid= 19684620 |doi= 10.1038/onc.2009.237  |author-separator=,  |author2=Yang H  |author3=Liu SG  |display-authors=3  |last4=Luo  |first4=M-L  |last5=Hao  |first5=J-J  |last6=Zhang  |first6=Y  |last7=Lin  |first7=D-C  |last8=Xu  |first8=X  |last9=Cai  |first9=Y }}
*{{cite journal  |author=Gelebart P, Opas M, Michalak M |title=Calreticulin, a Ca2+-binding chaperone of the endoplasmic reticulum |journal=Int. J. Biochem. Cell Biol. |volume=37 |issue= 2 |pages= 260–6 |year= 2005 |pmid= 15474971 |doi= 10.1016/j.biocel.2004.02.030 }}
*{{cite journal  |author=Qiu Y, Michalak M |title=Transcriptional control of the calreticulin gene in health and disease |journal=Int. J. Biochem. Cell Biol. |volume=41 |issue= 3 |pages= 531–8 |year= 2009 |pmid= 18765291 |doi= 10.1016/j.biocel.2008.06.020 }}
*{{cite journal  |author=Zhu Y |title=Calreticulin Controls the Rate of Assembly of CD1d Molecules in the Endoplasmic Reticulum |journal=J. Biol. Chem. |volume=285 |issue= 49 |pages= 38283–92 |year= 2010 |pmid= 20861015 |doi= 10.1074/jbc.M110.170530  |author-separator=,  |author2=Zhang W  |author3=Veerapen N  |display-authors=3  |last4=Besra  |first4=G.  |last5=Cresswell  |first5=P.  |pmc=2992262 }}
*{{cite journal  |author=Talmud PJ |title=Gene-centric Association Signals for Lipids and Apolipoproteins Identified via the HumanCVD BeadChip |journal=Am. J. Hum. Genet. |volume=85 |issue= 5 |pages= 628–42 |year= 2009 |pmid= 19913121 |doi= 10.1016/j.ajhg.2009.10.014 |pmc=2775832  |author-separator=,  |author2=Drenos F  |author3=Shah S  |display-authors=3  |last4=Shah  |first4=Tina  |last5=Palmen  |first5=Jutta  |last6=Verzilli  |first6=Claudio  |last7=Gaunt  |first7=Tom R.  |last8=Pallas  |first8=Jacky  |last9=Lovering  |first9=Ruth}}
*{{cite journal  |author=Taner SB |title=Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention |journal=J. Immunol. |volume=186 |issue= 1 |pages= 62–72 |year= 2011 |pmid= 21115737 |doi= 10.4049/jimmunol.0903657  |author-separator=,  |author2=Pando MJ  |author3=Roberts A  |display-authors=3  |last4=Schellekens  |first4=J.  |last5=Marsh  |first5=S. G. E.  |last6=Malmberg  |first6=K.-J.  |last7=Parham  |first7=P.  |last8=Brodsky  |first8=F. M.  |pmc=3129036 }}
*{{cite journal  |author=Tarr JM |title=Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells |journal=Arthritis Rheum. |volume=62 |issue= 10 |pages= 2919–29 |year= 2010 |pmid= 20533543 |doi= 10.1002/art.27602  |author-separator=,  |author2=Winyard PG  |author3=Ryan B  |display-authors=3  |last4=Harries  |first4=Lorna W.  |last5=Haigh  |first5=Richard  |last6=Viner  |first6=Nick  |last7=Eggleton  |first7=Paul }}
*{{cite journal  |author=Kepp O |title=Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death |journal=Cell Cycle |volume=9 |issue= 15 |pages= 3072–7 |year= 2010 |pmid= 20699648 |doi= 10.4161/cc.9.15.12459  |author-separator=,  |author2=Gdoura A  |author3=Martins I  |display-authors=3  |last4=Panaretakis  |first4=Theocharis  |last5=Schlemmer  |first5=Frederic  |last6=Tesniere  |first6=Antoine  |last7=Fimia  |first7=Gian Maria  |last8=Ciccosanti  |first8=Fabiola  |last9=Burgevin  |first9=Anne }}
*{{cite journal  |author=Sato H, Azuma Y, Higai K, Matsumoto K |title=Altered expression of glycoproteins on the cell surface of Jurkat cells during etoposide-induced apoptosis: shedding and intracellular translocation of glycoproteins |journal=Biochim. Biophys. Acta |volume=1790 |issue= 10 |pages= 1198–205 |year= 2009 |pmid= 19524015 |doi= 10.1016/j.bbagen.2009.05.019 }}
*{{cite journal  |author=Hong C |title=Functional analysis of recombinant calreticulin fragment 39-272: implications for immunobiological activities of calreticulin in health and disease |journal=J. Immunol. |volume=185 |issue= 8 |pages= 4561–9 |year= 2010 |pmid= 20855873 |doi= 10.4049/jimmunol.1000536  |author-separator=,  |author2=Qiu X  |author3=Li Y  |display-authors=3  |last4=Huang  |first4=Q.  |last5=Zhong  |first5=Z.  |last6=Zhang  |first6=Y.  |last7=Liu  |first7=X.  |last8=Sun  |first8=L.  |last9=Lv  |first9=P. }}
*{{cite journal  |author=Alur M |title=Suppressive Roles of Calreticulin in Prostate Cancer Growth and Metastasis |journal=Am. J. Pathol. |volume=175 |issue= 2 |pages= 882–90 |year= 2009 |pmid= 19608864 |doi= 10.2353/ajpath.2009.080417  |author-separator=,  |author2=Nguyen MM  |author3=Eggener SE  |display-authors=3  |last4=Jiang  |first4=Feng  |last5=Dadras  |first5=Soheil S.  |last6=Stern  |first6=Jeffrey  |last7=Kimm  |first7=Simon  |last8=Roehl  |first8=Kim  |last9=Kozlowski  |first9=James  |pmc=2716982 }}
*{{cite journal  |author=Bailey SD |title=Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study |journal=Diabetes Care |volume=33 |issue= 10 |pages= 2250–3 |year= 2010 |pmid= 20628086 |doi= 10.2337/dc10-0452 |pmc=2945168  |author-separator=,  |author2=Xie C  |author3=Do R  |display-authors=3  |last4=Montpetit  |first4=A.  |last5=Diaz  |first5=R.  |last6=Mohan  |first6=V.  |last7=Keavney  |first7=B.  |last8=Yusuf  |first8=S.  |last9=Gerstein  |first9=H. C.}}
*{{cite journal  |author=Nabi MO |title=Novel mutations in the calreticulin gene core promoter and coding sequence in schizoaffective disorder |journal=Am. J. Med. Genet. B Neuropsychiatr. Genet. |volume=153B |issue= 2 |pages= 706–9 |year= 2010 |pmid= 19760677 |doi= 10.1002/ajmg.b.31036  |author-separator=,  |author2=Mirabzadeh A  |author3=Feizzadeh G  |display-authors=3  |last4=Khorram Khorshid  |first4=H.R.  |last5=Karimlou  |first5=M.  |last6=Zarif Yeganeh  |first6=M.  |last7=Asgharian  |first7=A.M.  |last8=Najmabadi  |first8=H.  |last9=Ohadi  |first9=M. }}
*{{cite journal  |author=Schardt JA |title=Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia |journal=J. Cell. Mol. Med. |volume=14 |issue= 6B |pages= 1509–19 |year= 2010 |pmid= 19659458 |doi= 10.1111/j.1582-4934.2009.00870.x  |author-separator=,  |author2=Eyholzer M  |author3=Timchenko NA  |display-authors=3  |last4=Mueller  |first4=Beatrice U.  |last5=Pabst  |first5=Thomas }}

{{refend}}

==External links==
* {{MeshName|Calreticulin}}


{{PDB Gallery|geneid=811}}
{{Calcium-binding proteins}}
{{Lectins}}

[[Category:C-type lectins]]
[[Category:Immune system]]
[[Category:Proteins]]
[[Category:Cell signaling]]
[[Category:Signal transduction]]